Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
14 evidence topics · 11 sources
Activating GNAQ and GNA11 mutations
“Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GNA11 and GNAQ Q209 mutations in primary tumors and metastases
“The frequency of mutations in GNA11 at the codon encoding Q209 increased progressively from blue nevi (6.5%) to primary uveal melanomas (31.9%) to uveal melanoma metastases (56.5%), a pattern inverse to the distribution of Q209 mutations in GNAQ, which are most common in blue nevi (54.7%) and least common in uveal melanoma metastases (21.7%) (P<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutually exclusive G-protein pathway mutations: GNAQ, GNA11, CYSLTR2, and PLCB4
CYSLTR2 mutation as a uveal melanoma oncogene
“We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Leu129Gln CysLT2R mutant protein constitutively activates endogenous Gαq and is unresponsive to stimulation by leukotriene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PLCB4 mutation as the downstream effector of Gαq signaling
Protein kinase C and MAPK pathway activation downstream of GNAQ and GNA11
“We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation, MAPK activation can be attributed to activated PKC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second driver event: BAP1, SF3B1, or EIF1AX
“After the GNAQ/GNA11 mutation, a second driver event is necessary for malignant transformation. The premalignant cells either present loss of function BAP1 or mutations in SF3B1 or EIF1AX. This second hit also occurs in a mutually exclusive fashion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP1 inactivation in metastasizing tumors and chromosome 3 loss
“Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One copy of chromosome 3 was missing in all 17 BAP1-mutant class 2 tumors for which cytogenetic data were available, consistent with chromosome 3 loss uncovering recessive BAP1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Four molecular subsets defined by chromosome 3 status, TCGA
“Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EIF1AX and SF3B1 mutations in 27 of the 80 UM (34%) were nearly mutually exclusive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognostic associations of BAP1, SF3B1, EIF1AX, MBD4, and PRAME
“Biallelic BAP1 inactivation is associated with high risk of metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Change-of-function SF3B1 mutations are associated with late metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutations in EIF1AX are associated with a better prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutations in MBD4 lead to a hypermutator phenotype, which has been correlated with improved response to immune checkpoint inhibitor (ICI) therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expression of PRAME (preferentially expressed antigen of melanoma) is associated with a higher risk of metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Low tumor mutational burden and absence of BRAF, NRAS, KIT, and NF1 mutations
Immunosuppressive tumor microenvironment
Hematogenous spread and liver tropism
“UM is characterised by early seeding and years of dormancy of micrometastases; the liver constitutes a specific niche, as numerous molecules like chemokine ligand 12 and chemokine receptor 4 (CXCL12/CXCR4) are involved in UM liver homing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MET expression in primary tumors and liver metastases
“Thirty-nine of 40 (98%) primary tumors and nine of 10 (90%) metastatic liver lesions expressed c-MET (H-score range 0-300).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“c-MET expression was significantly higher in metastatic compared with primary tumors (median H-score 190 vs. 30, P=0.022).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote